<DOC>
	<DOCNO>NCT02960724</DOCNO>
	<brief_summary>uPAR PET/CT Staging Advanced Localised oral oropharyngeal cancer</brief_summary>
	<brief_title>uPAR PET/CT Staging Advanced Localised Oral Oropharyngeal Cancer</brief_title>
	<detailed_description>To compare diagnostic value uPAR-PET/CT prognostication compare current imaging option ( CT , MRI ultrasound ) observer-blinded reading . The reference use `` gold standard '' pathological examination surgically remove tissue . The new imaging modality ( uPAR-PET/CT ) use two separate group patient head neck cancer : Study I : Patients oral cancer without clinical evidence spread ( OSCC stage cN0 ) Study II : Patients metastatic oral cancer ( OSCC stage cN + ) patient metastatic oropharyngeal cancer ( OPSCC stage cN + ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Neoplasms Site</mesh_term>
	<criteria>Able understand patient information give inform consent Not previously irradiate operated neck Operable disease Study I OSCC cN0 verify histologically pathologic examination biopsy Study II OSCC OPSCC N + verify histologically pathologic examination biopsy Pregnancy Patients candidate curative intentional radiation Patients surgery radiation therapy neck may alter lymph drainage . Other disease assess investigator basis exclusion . Age 18 85 year Obesity &gt; 140 kg Allergy 68GaNOTAAE105</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Uroplasminogen Plasminogen Activator Receptor</keyword>
	<keyword>Oropharyngeal cancer</keyword>
	<keyword>oral cancer</keyword>
	<keyword>Positron Emission Tomography</keyword>
</DOC>